Inhibikase Therapeutics, INC 10-Q quarterly reports

Inhibikase Therapeutics, Inc. (IKT) filed its Q2 2026 10-Q, detailing increased R&D expenses, a substantial net loss of $19.6 million for the quarter, and highlighting the critical need for future capital raises to sustain operations.

Inhibikase Therapeutics reports increased R&D spending and SG&A costs in Q1 2026, with cash reserves sufficient for at least 12 months.

Inhibikase reported a larger Q3 net loss as it ramps spending ahead of a Phase 2b PAH trial, ending the quarter with $77.3 million in cash and securities and targeting a Q4 2025 study start.

Inhibikase Therapeutics reports increased R&D spend and net loss in Q2 2025, driven by its lead PAH program, while maintaining a strong cash position and securing future funding options.

Inhibikase Therapeutics reports its financial results for the first quarter of 2025, highlighting progress in its PAH program and recent corporate developments.

Inhibikase Therapeutics announced its Q3 2024 financial results, highlighting a net loss but also securing a significant $110 million private placement to advance its clinical programs.

Inhibikase Therapeutics announced its second quarter 2024 financial results, highlighting progress in clinical trials and ongoing development of its drug candidates.

Inhibikase Therapeutics reported its first quarter 2024 financial results, highlighting progress in its clinical programs for Parkinson's disease and other neurodegenerative disorders.